DAX23.791 -3,4%Est505.772 -3,6%MSCI World4.343 -0,1%Top 10 Crypto8,7800 -3,5%Nas22.564 -0,8%Bitcoin59.172 +0,6%Euro1,1620 -0,6%Öl80,79 +3,5%Gold5.132 -3,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
freenet A0Z2ZZ AIXTRON A0WMPJ E.ON ENAG99 Münchener Rückversicherungs-Gesellschaft 843002 Heidelberg Materials 604700 Tesla A1CX3T Vonovia A1ML7J BioNTech (ADRs) A2PSR2 NEL ASA A0B733 AMD (Advanced Micro Devices) 863186 RWE 703712 Airbus 938914 Rolls-Royce A1H81L TKMS thyssenkrupp Marine Systems TKMS00 Micron Technology 869020
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nahostkonflikt: DAX rauscht letztlich unter 23.800-Punkte-Marke -- Plug Power: Mehr Umsatz -- Palantir, MongoDB, Micron, NVIDIA, AMD, Apple, Rüstungsaktien, Vonovia, TUI, BestBuy im Fokus
Top News
So viel hätte eine Investition in Stellar von vor 3 Jahren abgeworfen So viel hätte eine Investition in Stellar von vor 3 Jahren abgeworfen
Cardano: So viel Verlust hätte ein Investment von vor 3 Jahren eingebracht Cardano: So viel Verlust hätte ein Investment von vor 3 Jahren eingebracht
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Alkermes Aktie

Kaufen
Verkaufen
25,60 EUR -0,20 EUR -0,78 %
STU
30,00 USD -0,25 USD -0,83 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.4,33 Mrd. EUR

KGV19,54Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1JKVH

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINIE00B56GVS15

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolALKS

Alkermes Aktien News

DatumMeistgelesen
PR NewswireAlkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
PR NewswireAlkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
PR NewswireAlkermes Response to Avadel Announcement
PR NewswireAlkermes Response to Avadel Announcement
PR NewswireAlkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
PR NewswireAlkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
PR NewswireAlkermes to Participate in Two Upcoming Investor Conferences
PR NewswireAlkermes to Participate in Two Upcoming Investor Conferences
PR NewswireFORM 8.1(a) & (b) (Opening Position Disclosure)
PR NewswireFORM 8.1(a) & (b) (Opening Position Disclosure)
PR NewswireAlkermes plc Reports Third Quarter 2025 Financial Results
PR NewswireAlkermes plc Reports Third Quarter 2025 Financial Results
PR NewswireAlkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
PR NewswireAlkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
PR NewswireAlkermes to Report Third Quarter Financial Results on October 28, 2025
PR NewswireAlkermes to Report Third Quarter Financial Results on October 28, 2025
PR NewswireAlkermes Appoints Joshua Reed as Chief Financial Officer
PR NewswireAlkermes Appoints Joshua Reed as Chief Financial Officer
PR NewswireAlkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
PR NewswireAlkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
PR NewswireAlkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
PR NewswireAlkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
PR NewswireAlkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
PR NewswireAlkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
PR NewswireAlkermes plc Reports Second Quarter 2025 Financial Results
PR NewswireAlkermes plc Reports Second Quarter 2025 Financial Results
PR NewswireAlkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
PR NewswireAlkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
PR NewswireAlkermes to Report Second Quarter Financial Results on July 29, 2025
PR NewswireAlkermes to Report Second Quarter Financial Results on July 29, 2025
PR NewswireAlkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
PR NewswireAlkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
PR NewswireAlkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
PR NewswireAlkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
PR NewswireAlkermes to Present New Research Related to ALKS 2680 at SLEEP 2025
PR NewswireAlkermes to Present New Research Related to ALKS 2680 at SLEEP 2025
PR NewswireAlkermes plc Reports First Quarter 2025 Financial Results
PR NewswireAlkermes plc Reports First Quarter 2025 Financial Results
PR NewswireNew Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)
PR NewswireNew Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)

Alkermes News

Alkermes News: auf dieser Seite finden Sie alle Alkermes News und Nachrichten zur Alkermes Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Alkermes News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Alkermes News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.